For how we live.
27 articles published between October 23, 2025 and October 5, 2026.
In the Nordic SWEDEGRAFT trial, the no-touch vein-harvesting technique left the rate of death, heart attack, or repeat procedures at 19.8% versus 20.4% through seven years — a difference indistinguishable from chance.
Some heart attacks leave scar on an ECG or MRI but were never felt as one. In a long US cohort they made up more than 45% of heart attacks — and they still shortened survival.
The crushing chest pressure is real and common. But in a registry of more than a million patients, 42% of women arrived without chest pain, against 31% of men — and the gap was widest in the young.
In heart patients, randomised trials link influenza vaccination to fewer cardiovascular events and deaths. The effect is clearest in the highest-risk patients, and the largest trial stopped early.
US preventive guidance recommends against a resting or exercise ECG in symptom-free adults at low cardiovascular risk, and finds the evidence insufficient at higher risk. The tracing rarely changes treatment.
It is not a routine test for everyone — the USPSTF finds the evidence insufficient. Cardiology guidelines back it for one group: intermediate-risk adults weighing whether to start a statin.
A French study of 11,558 patients without heart failure linked atenolol to fewer cardiovascular events than bisoprolol. It is observational, so it shows an association, not proof one is better.
A large treadmill cohort found the least-fit adults had about five times the death rate of the fittest — a bigger risk than coronary disease, smoking or diabetes. But it measures a state, not a lever.
In a 64-patient randomised trial, home cardiac rehab monitored by a smart ring improved fitness. But both arms wore the ring; what separated them was a weekly call from a clinician.
Colder days track with more heart attacks in nationwide data, and the sharpest signal is the day after heavy snowfall — a rise seen in men but not women, pointing to the shovel as much as the temperature.
Every low-dose CT for lung cancer also images the heart. A 323-scan study found an AI tool matched expert calcium scoring almost exactly — and separate data show why that number carries weight.
A Mediterranean diet rich in extra-virgin olive oil cut cardiovascular events in a Spanish trial, and US cohorts link over half a tablespoon a day to less heart disease — the biggest signal in what it replaces.
Two trials found low-dose colchicine cut cardiovascular events, and the FDA approved it for heart risk in 2023. Then the largest trial found nothing, leaving the question genuinely unsettled.
Pooled across 85 trials, exercise-based cardiac rehab cut later heart attacks and hospital admissions but barely moved death rates within a year — a real benefit, and a narrower one than the usual pitch.
EVAOLD tested whether stress imaging could safely spare patients aged 80 and over an invasive procedure. It was stopped early for futility, and the selective strategy did not prove non-inferior.
In 408,039 UK Biobank participants, carrying loss-of-function variants in both LPA and PCSK9 was tied to markedly lower coronary disease risk than either alone — a genetic case for combination therapy.
In a randomised trial of 3,102 bypass patients across seven countries, all-cause mortality was near-identical between bilateral and single internal thoracic artery grafting.
TARGET-CTCA randomised 3,170 emergency patients whose troponin had cleared them of a heart attack. Outpatient CT angiography-guided care matched standard care on later infarction or cardiac death.
The REACT study imaged people aged 18 to 70 with no known cardiovascular disease. Atherosclerosis was already present in some people in their twenties, and it was usually in the legs, not the heart.
PREMIUM tested prasugrel alone against aspirin plus prasugrel in 2,216 STEMI patients in Japan. Monotherapy failed to show noninferiority, and the confidence interval sat above one.
ABYSS and SMART-DECISION together cover 6,238 stable patients. Discontinuation cleared both noninferiority margins, though the authors say the primary endpoint's composition limits what it shows.
LIBREXIA-ACS enrolled 14,194 patients before stopping for futility. Milvexian did not reduce events, but intracranial and fatal bleeding were identical to placebo, which is the class's whole premise.
A meta-analysis of 45 cohorts found risk rising steadily with every 10 beats per minute. A study of 92,457 wearable users found one person's normal can differ from another's by 70 beats.
Pooling 11 cohort studies, researchers found a consistent cardiovascular signal in Asian and North American cohorts. European cohorts showed no elevated risk at all, a geographic split the analysis can't explain.
Nearly twice as many CPAP-treated patients saw their HFpEF-like markers improve at one year compared with those who went untreated — in a population sleep specialists have historically deprioritized for treatment.
Thirty-five people received VERVE-102 in a phase 1 trial. The edit is permanent, the follow-up is short, and the endpoint measured was cholesterol, not heart attacks.
PpgAge predicts chronological age from consumer wearable photoplethysmography and tracks disease. The same optical method has documented accuracy problems across skin tones.